MedTrace Logo

Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation

NCT01414660 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2018-06-07

No results posted yet for this study

Summary

Three different white adipose tissue-related disorders, whether due to its excess (obesity), absence (lipoatrophies) or aberrant distribution (lipodystrophies), are paradoxically able to induce metabolic insulin resistance syndrome. The respective roles played by quantitative and qualitative anomalies of adipose tissue, gluco- and lipo-toxicity, liver and muscle insulin resistance, low-grade fat inflammation and immune alterations are not yet perfectly understood. In contrast to most organ transplantations that are often complicated by post-transplantation diabetes, diabetes cell therapy is associated with body weight loss, which is possibly related to the antiadipogenic effects of mTOR inhibitors (rapamycin or sirolimus). The aim of this study is thus to determine and monitor blood interleukin-7 and other cytokine levels; metabolic parameters; and fat mass distribution with DEXA and RMN, before and after a immunosuppressive regimen in patients receiving different kinds of transplantation (liver, kidney or islets) with normal weight and no type 2 diabetes before transplantation. In these patients, blood samples will be taken before and after transplantation, as will adipose tissue during the transplantation surgery, in order to constitute a plasma serum, gene and tissue bank for improving our knowledge of disorders linking fat mass, insulin resistance and immunity, especially post-transplantation diabetes.

Conditions

  • Immunodeficiency Secondary to Organ Transplantation

Interventions

PROCEDURE

transplantation

transplantation of islet, kidney or liver

Sponsors & Collaborators

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Marie-Christine VANTYGHEM, MD, PhD · Lille University Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-09
Primary Completion
2018-02-28
Completion
2018-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01414660 on ClinicalTrials.gov